REFERENCES
- McCuen B W, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981; 91: 785–788, [PUBMED], [INFOTRIEVE], [CSA]
- Schindler R H, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982; 93: 415–417, [PUBMED], [INFOTRIEVE], [CSA]
- Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980; 90: 810–816, [PUBMED], [INFOTRIEVE], [CSA]
- Wilson C A, Berkowitz B A, Sato Y, Ando N, Handa J T, de Juan E., jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992; 110: 1155–1159, [PUBMED], [INFOTRIEVE], [CSA]
- Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan S J. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1985; 103: 708–711, [PUBMED], [INFOTRIEVE], [CSA]
- Antoszyk A N, Gottlieb J L, Machemer R, Hatchell D L. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1993; 231: 34–40, [PUBMED], [INFOTRIEVE], [CSA]
- Challa J K, Gillies M C, Penfold P L, Gyory J F, Hunyor A B, Billson F A. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZ J Ophthalmol. 1998; 26: 277–281, [CSA]
- Gillies M C, Simpson J M, Luo W, Penfold P, Hunyor A B, Chua W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003; 121: 667–673, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B, Degenring R F, Kreissig I, Friedemann T, Akkoyun I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye. 2005; 19: 163–170, [PUBMED], [INFOTRIEVE], [CSA]
- Benitez Del Castillo Sanchez J M, Garcia S J. [Intravitreal injection of triamcinolone acetonide in non infectious uveitis]. Arch Soc Esp Oftalmol. 2001; 76: 661–664, [PUBMED], [INFOTRIEVE], [CSA]
- Kramer M, Ehrlich R, Snir M, Friling R, Mukamel M, Weinberger D, et al. Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behçet's disease. Am J Ophthalmol. 2004; 138: 666–667, [PUBMED], [INFOTRIEVE], [CSA]
- Sutter F K, Simpson J M, Gillies M C. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004; 111: 2044–2049, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B, Degenring R F, Kamppeter B A, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol. 2004; 138: 158–160, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B, Kreissig I, Sofker A, Degenring R F. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003; 121: 57–61, [PUBMED], [INFOTRIEVE], [CSA]
- Massin P, Audren F, Haouchine B, Erginay A, Bergmann J F, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004; 111: 218–224, [PUBMED], [INFOTRIEVE], [CSA]
- Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand. 2003; 81: 648–652, [PUBMED], [INFOTRIEVE], [CSA]
- Conway M D, Canakis C, Livir-Rallatos C, Peyman G A. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg. 2003; 29: 27–33, [PUBMED], [INFOTRIEVE], [CSA]
- Antcliff R J, Spalton D J, Stanford M R, Graham E M, Ffytche T J, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001; 108: 765–772, [PUBMED], [INFOTRIEVE], [CSA]
- Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol. 2001; 29: 2–6, [CSA]
- Karacorlu M, Mudun B, Ozdemir H, Karacorlu S A, Burumcek E. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am J Ophthalmol. 2004; 138: 289–291, [PUBMED], [INFOTRIEVE], [CSA]
- Park C H, Jaffe G J, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003; 136: 419–425, [PUBMED], [INFOTRIEVE], [CSA]
- Bashshur Z F, Ma'luf R N, Allam S, Jurdi F A, Haddad R S, Noureddin B N. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol. 2004; 122: 1137–1140, [PUBMED], [INFOTRIEVE], [CSA]
- Ip M S, Gottlieb J L, Kahana A, Scott I U, Altaweel M M, Blodi B A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004; 122: 1131–1136, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B, Hayler J K, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000; 84: 1064–1067, [PUBMED], [INFOTRIEVE], [CSA]
- Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol. 2002; 240: 423–429, [PUBMED], [INFOTRIEVE], [CSA]
- Degenring R F, Jonas J B. Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004; 137: 1142–1143, [PUBMED], [INFOTRIEVE], [CSA]
- Suttorp-Schulten M S, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996; 80: 844–848, [PUBMED], [INFOTRIEVE], [CSA]
- Rothova A, Suttorp-van Schulten M S, Treffers W F, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996; 80: 332–336, [PUBMED], [INFOTRIEVE], [CSA]
- Durrani O M, Tehrani N N, Marr J E, Moradi P, Stavrou P, Murray P I. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004; 88: 1159–1162, [PUBMED], [INFOTRIEVE], [CSA]
- Degenring R F, Jonas J B. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol. 2003; 87: 361, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B. Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. Am J Ophthalmol. 2004; 137: 367–368, [PUBMED], [INFOTRIEVE], [CSA]
- Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide in sympathetic ophthalmia. Graefes Arch Clin Exp Ophthalmol. 2005; 243: 734–736, [PUBMED], [INFOTRIEVE], [CSA]
- Shah G K, Stein J D, Sharma S, Sivalingam A, Benson W E, Regillo C D, et al. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology. 2000; 107: 486–489, [PUBMED], [INFOTRIEVE], [CSA]
- Das T, Jalali S, Gothwal V K, Sharma S, Naduvilath T J. Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. Br J Ophthalmol. 1999; 83: 1050–1055, [PUBMED], [INFOTRIEVE], [CSA]
- Martidis A, Duker J S, Puliafito C A. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol. 2001; 119: 1380–1383, [PUBMED], [INFOTRIEVE], [CSA]
- Sorensen T L, Haamann P, Villumsen J, Larsen M. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. Acta Ophthalmol Scand. 2005; 83: 67–70, [PUBMED], [INFOTRIEVE], [CSA]
- Mason J O, III, Somaiya M D, Singh R J. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina. 2004; 24: 900–904, [PUBMED], [INFOTRIEVE], [CSA]
- Audren F, Tod M, Massin P, Benosman R, Haouchine B, Erginay A, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004; 45: 3435–3441, [PUBMED], [INFOTRIEVE], [CSA]
- Beer P M, Bakri S J, Singh R J, Liu W, Peters G B, III, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003; 110: 681–686, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004; 137: 560–562, [PUBMED], [INFOTRIEVE], [CSA]
- Jager R D, Aiello L P, Patel S C, Cunningham E T., jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004; 24: 676–698, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B, Kreissig I, Degenring R F. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol. 2003; 121: 1663–1664, [PUBMED], [INFOTRIEVE], [CSA]
- Moshfeghi A A, Scott I U, Flynn H W, jr, Puliafito C A. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol. 2004; 138: 489–492, [PUBMED], [INFOTRIEVE], [CSA]
- Nelson M L, Tennant M T, Sivalingam A, Regillo C D, Belmont J B, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003; 23: 686–691, [PUBMED], [INFOTRIEVE], [CSA]
- Roth D B, Chieh J, Spirn M J, Green S N, Yarian D L, Chaudhry N A. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003; 121: 1279–1282, [PUBMED], [INFOTRIEVE], [CSA]
- Moshfeghi D M, Kaiser P K, Scott I U, Sears J E, Benz M, Sinesterra J P, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003; 136: 791–796, [PUBMED], [INFOTRIEVE], [CSA]
- Ta C N. Minimizing the risk of endophthalmitis following intravitreous injections. Retina. 2004; 24: 699–705, [PUBMED], [INFOTRIEVE], [CSA]
- Aiello L P, Brucker A J, Chang S, Cunningham E T, jr, D'Amico D J, Flynn H W, jr, et al. Evolving guidelines for intravitreous injections. Retina. 2004; 24: S3–19, [PUBMED], [INFOTRIEVE], [CSA]
- Gillies M C, Simpson J M, Billson F A, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004; 122: 336–340, [PUBMED], [INFOTRIEVE], [CSA]
- Wingate R J, Beaumont P E. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol. 1999; 27: 431–432, [CSA]
- Smithen L M, Ober M D, Maranan L, Spaide R F. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004; 138: 740–743, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B, Degenring R F, Kreissig I, Akkoyun I, Kamppeter B A. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005; 112: 593–598, [PUBMED], [INFOTRIEVE], [CSA]
- Helm C J, Holland G N. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995; 120: 55–64, [PUBMED], [INFOTRIEVE], [CSA]
- Lafranco D M, Tran V T, Guex-Crosier Y, Herbort C P. Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol. 1999; 237: 289–295, [CSA]
- Singh I P, Ahmad S I, Yeh D, Challa P, Herndon L W, Allingham R R, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2004; 138: 286–287, [PUBMED], [INFOTRIEVE], [CSA]
- Agrawal S, Agrawal J, Agrawal T P. Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 2004; 138: 679–680, [PUBMED], [INFOTRIEVE], [CSA]
- Kaushik S, Gupta V, Gupta A, Dogra M R, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol. 2004; 137: 758–760, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003; 87: 24–27, [PUBMED], [INFOTRIEVE], [CSA]
- Jonas J B, Degenring R, Kreissig I, Akkoyun I. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol. 2004; 138: 1054–1055, [PUBMED], [INFOTRIEVE], [CSA]
- Baudouin C, Chassain C, Caujolle C, Gastaud P. Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmologica. 1996; 210: 329–335, [PUBMED], [INFOTRIEVE], [CSA]
- Penfold P L, Gyory J F, Hunyor A B, Billson F A. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust NZ J Ophthalmol. 1995; 23: 293–298, [CSA]
- Jonas J B, Kreissig I, Degenring R F. Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye. 2004; 18: 361–364, [PUBMED], [INFOTRIEVE], [CSA]
- Gillies M C, Kuzniarz M, Craig J, Ball M, Luo W, Simpson J M. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005; 112: 139–143, [PUBMED], [INFOTRIEVE], [CSA]
- Modarres M, Parvaresh M M, Peyman G A. Accidental subretinal injection of triamcinolone acetonide. Ophthalmic Surg Lasers. 1998; 29: 935–938, [PUBMED], [INFOTRIEVE], [CSA]
- Garcia-Arumi J, Boixadera A, Giralt J, Martinez-Castillo V, Gomez-Ulla F, Corcostegui B, et al. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol. 2005; 89: 1112–1114, [PUBMED], [INFOTRIEVE], [CSA]